From Protocol to Patient Risk: How to Build Safer, Faster Trials by Integrating Clinical Operations and Pharmacovigilance Early

Clinical execution and pharmacovigilance are often managed in parallel rather than in partnership. For sponsors, that disconnect can create avoidable delays, inconsistent safety decision-making, protocol amendments, and added pressure on sites and study teams. In early-phase and complex trials, where risk profiles are still emerging, these gaps can have a direct impact on both patient safety and development timelines.

Join experts from Ergomed Clinical Research and PrimeVigilance for a practical discussion on how earlier integration across clinical operations, medical monitoring, and pharmacovigilance can strengthen study oversight from the outset. This webinar will examine where silos tend to emerge, how integrated planning can reduce downstream issues, and what sponsors can do to build a more connected model across protocol strategy, trial conduct, individual case safety report handling, and signal and risk management.

Attendees will gain practical insight into how a more aligned clinical and safety strategy can support better benefit-risk decisions, reduce operational risk, and help keep complex studies on track.

Key Takeaways:
– Why separating clinical operations and safety oversight creates avoidable risk in clinical development
– Where silos most often create issues, including delayed decisions, protocol amendments, inconsistent safety data handling incl. signal and risk management, and added site burden
– What integrated planning and execution looks like in practice across study design, medical monitoring, pharmacovigilance, and trial conduct
– How earlier collaboration can support stronger decision-making, operational readiness, and timeline protection
– Practical ways to reduce downstream risk while improving both patient safety and study efficiency